期刊
RNA BIOLOGY
卷 19, 期 1, 页码 364-372出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/15476286.2022.2043650
关键词
Friedrich's Ataxia; Frataxin; Antisense oligonucleotide; Trinucleotide repeat
资金
- National Institute of General Medical Sciences from the National Institutes of Health [R35GM118103]
- Robert A. Welch Foundation [I-1244]
- Friedreich's Ataxia Research Alliance
- Paul D. Wellstone MDCRC Trainee Fellowship Award from UT Southwestern Medical Center
- Muscular Dystrophy Association [MDA418838]
- National Institutes of Health [R01NS081366]
This study investigated the potential of using oligonucleotides to increase frataxin expression in a mouse model for Friedreich's ataxia, but found that various mechanisms designed anti-FXN oligonucleotides did not enhance FXN expression in the model mice. The inability to translate activation of FXN expression from cell culture to mice may be due to inadequate potency of the compounds or differences in the molecular mechanisms governing FXN gene repression and activation in the FA model mice.
Friedreich's ataxia (FA) is an inherited neurodegenerative disorder caused by decreased expression of frataxin (FXN) protein. Previous studies have shown that antisense oligonucleotides (ASOs) and single-stranded silencing RNAs can be used to increase expression of frataxin in cultured patient-derived cells. In this study, we investigate the potential for oligonucleotides to increase frataxin expression in a mouse model for FA. After confirming successful in vivo delivery of oligonucleotides using a benchmark gapmer targeting the nuclear noncoding RNA Malat1, we tested anti-FXN oligonucleotides designed to function by various mechanisms. None of these strategies yielded enhanced expression of FXN in the model mice. Our inability to translate activation of FXN expression from cell culture to mice may be due to inadequate potency of our compounds or differences in the molecular mechanisms governing FXN gene repression and activation in FA model mice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据